1
|
Mardones C, Navarrete-Munoz C, Armijo ME, Salgado K, Rivas-Valdes F, Gonzalez-Pecchi V, Farkas C, Villagra A, Hepp MI. Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells. Mol Immunol 2023; 164:98-111. [PMID: 37992541 DOI: 10.1016/j.molimm.2023.11.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 09/15/2023] [Accepted: 11/13/2023] [Indexed: 11/24/2023]
Abstract
Colorectal cancer (CRC) is one of the most common malignant neoplasms and the second leading cause of death from tumors worldwide. Therefore, there is a great need to study new therapeutical strategies, such as effective immunotherapies against these malignancies. Unfortunately, many CRC patients do not respond to current standard immunotherapies, making it necessary to search for adjuvant treatments. Histone deacetylase 6 (HDAC6) is involved in several processes, including immune response and tumor progression. Specifically, it has been observed that HDAC6 is required to activate the Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor involved in immunogenicity, by activating different genes in these pathways, such as PD-L1. Over-expression of immunosuppressive pathways in cancer cells deregulates T-cell activation. Therefore, we focused on the pharmacological inhibition of HDAC6 in CRC cells because of its potential as an adjuvant to avoid immunotolerance in immunotherapy. We investigated whether HDAC6 inhibitors (HDAC6is), such as Nexturastat A (NextA), affected STAT3 activation in CRC cells. First, we found that NextA is less cytotoxic than the non-selective HDACis panobinostat. Then, NextA modified STAT3 and decreased the mRNA and protein expression levels of PD-L1. Importantly, transcriptomic analysis showed that NextA treatment affected the expression of critical genes involved in immunomodulatory pathways in CRC malignancies. These results suggest that treatments with NextA reduce the functionality of STAT3 in CRC cells, impacting the expression of immunomodulatory genes involved in the inflammatory and immune responses. Therefore, targeting HDAC6 may represent an interesting adjuvant strategy in combination with immunotherapy.
Collapse
Affiliation(s)
- C Mardones
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - C Navarrete-Munoz
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - M E Armijo
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - K Salgado
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - F Rivas-Valdes
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile; Facultad de Medicina y Ciencia, Universidad San Sebastián, Concepción, Chile
| | - V Gonzalez-Pecchi
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - C Farkas
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile
| | - A Villagra
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC 20057, United States
| | - M I Hepp
- Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 4090541, Chile.
| |
Collapse
|
2
|
Sixto-López Y, Bello M, Correa-Basurto J. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6. J Biomol Struct Dyn 2019; 37:4701-4720. [PMID: 30558483 DOI: 10.1080/07391102.2018.1557560] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
HDAC6 is a protein involved in cancer, neurodegenerative disease and inflammatory disorders. To date, the full three-dimensional (3D) structure of human HDAC6 has not been elucidated; however, there are some experimental 3D structural homologs to HDAC6 that can be used as templates. In this work, we utilized molecular modeling procedures to model both of the catalytic domains of HDAC6 connected by the linker region where DMB region is placed. Once the 3D structure of human HDAC6 was obtained, it was structurally evaluated and submitted to docking and molecular dynamic (MD) simulations along with Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method to explore the stability and the binding free energy properties of the HDAC6-ligand complexes. In addition, its structural and energetic behavior was explored with each one of the catalytic domains in the molecular recognition of six selective HDAC6 inhibitors, HPOB, CAY10603, Nexturastat, Rocilinostat, Tubacin and Tubastatin A for DD2, and with the so-called 9-peptide which is DD1-HDAC6 selective substrate. The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with experimental reports. However, 9-peptide showed a higher affinity for DD1, which agrees with experimental reports elsewhere. Principal component analysis provided important information about the structural changes linked to the molecular recognition process, whereas per-residue decomposition analysis revealed the energetic contribution of the key residues in the molecular binding and structural characteristics that could assist in drug design.
Collapse
Affiliation(s)
- Yudibeth Sixto-López
- Laboratorio de Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory of Drug Development and Biotechnology Innovation), Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City , Mexico
| | - Martiniano Bello
- Laboratorio de Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory of Drug Development and Biotechnology Innovation), Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City , Mexico
| | - José Correa-Basurto
- Laboratorio de Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory of Drug Development and Biotechnology Innovation), Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City , Mexico
| |
Collapse
|
3
|
M L, P PV, T K, M P, E S, J P, K V W, C L, F C, S D, M SKS, M M, A K, J PI, A S, E S, J W, E M S, A V. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol 2016; 10:735-750. [PMID: 26775640 DOI: 10.1016/j.molonc.2015.12.012] [Citation(s) in RCA: 111] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 12/14/2015] [Accepted: 12/15/2015] [Indexed: 01/02/2023] Open
Abstract
Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the expression of PD-L1, an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells. Our data suggests that this novel mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3. Additionally, we observed that selective HDAC6 inhibitors impairs tumor growth and reduce the in vivo expression of several inhibitory check-point molecules and other regulatory pathways involved in immunosurveillance. Most importantly, these results provide a key pre-clinical rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer.
Collapse
Affiliation(s)
- Lienlaf M
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Perez-Villarroel P
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Knox T
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Pabon M
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Sahakian E
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Powers J
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Woan K V
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Lee C
- All Children's Hospital, Johns Hopkins Medicine, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Cheng F
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Deng S
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Smalley K S M
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Montecino M
- Center for Biomedical Research and FONDAP Center for Genome Regulation, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | | | - Pinilla-Ibarz J
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Sarnaik A
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | - Seto E
- George Washington University
| | - Weber J
- H. Lee Moffitt Cancer Center, Faculty of Biological Sciences and Faculty of Medicine, Universidad Andres Bello
| | | | | |
Collapse
|
4
|
Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 2015; 9:1447-1457. [PMID: 25957812 DOI: 10.1016/j.molonc.2015.04.002] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 02/20/2015] [Accepted: 04/08/2015] [Indexed: 01/31/2023] Open
Abstract
The median survival for metastatic melanoma is in the realm of 8-16 months and there are few therapies that offer significant improvement in overall survival. One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells. Our group and others have previously demonstrated that pan-HDAC inhibitors induce apoptosis, cell cycle arrest and changes in the immunogenicity of melanoma cells. Here we interrogated specific HDACs which may be responsible for this effect. We found that both genetic abrogation and pharmacologic inhibition of HDAC6 decreases in vitro proliferation and induces G1 arrest of melanoma cell lines without inducing apoptosis. Moreover, targeting this molecule led to an important upregulation in the expression of tumor associated antigens and MHC class I, suggesting a potential improvement in the immunogenicity of these cells. Of note, this anti-melanoma activity was operative regardless of mutational status of the cells. These effects translated into a pronounced delay of in vivo melanoma tumor growth which was, at least in part, dependent on intact immunity as evidenced by the restoration of tumor growth after CD4+ and CD8+ depletion. Given our findings, we provide the initial rationale for the further development of selective HDAC6 inhibitors as potential therapeutic anti-melanoma agents.
Collapse
Affiliation(s)
- K V Woan
- H. Lee Moffitt Cancer Center, USA
| | | | | | - C Lee
- All Children's Hospital, Johns Hopkins Medicine, USA
| | - F Cheng
- H. Lee Moffitt Cancer Center, USA
| | - T Knox
- H. Lee Moffitt Cancer Center, USA
| | | | | | - J Powers
- H. Lee Moffitt Cancer Center, USA
| | | | - H W Wang
- H. Lee Moffitt Cancer Center, USA
| | | | | | | | - J Bergman
- University of Illinois at Chicago, USA
| | - E Seto
- H. Lee Moffitt Cancer Center, USA
| | | | | | | | - E Celis
- Georgia Regents University, USA
| | - J Weber
- H. Lee Moffitt Cancer Center, USA
| | | | | |
Collapse
|